Compass Bio - רווח נקי למניה בארבעת הרבעונים האחרונים CMPX
The immuno-oncology industry relies on external contractors to conduct tests, which minimizes operational disruptions for Compass Therapeutics (CMPX). Compass Therapeutics (CMPX) creates unique bispecific antibodies for a dual strike on tumors, attracting top developers through a flexible culture and stock options. Measuring the annual EPS TTM growth visualizes profit dynamics, where the value 10.30 describes the current level of earnings per share.
CMPX (Compass Bio): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Institutional capital evaluates Compass Therapeutics (CMPX) through the lens of R&D expenditures, as the absence of commercial sales renders traditional profit secondary. This annual percentage change in earnings per share (ttm) measures net income dynamics over 12 months, transforming quarterly reports into a continuous trend, which, given the company's lack of pricing power, turns this chart into an indicator of capital burn efficiency.
